Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: Keiko who wrote (9260)	5/8/1998 8:05:00 PM
From: Scott H. Davis	Respond to of 14328

Quick followup thought in Viagra & how to hopefully avoid needing it. Don't smoke. Seriously, smoking is a key contributor to peripheral vascular disease (reduced blood flow to the extremities) Obviously, other lifestyle habits also help - good diet and exersize are inversely correlated to PVD. Keep your blood supply system in good shape..... Scott

To: Keiko who wrote (9260)	5/9/1998 7:52:00 PM
From: Ace	Read Replies (1) \| Respond to of 14328

TID-BIT... Trypanosoma cruzi ("T. cruzi"). T. cruzi is an intracellular blood and tissue parasite endemic to South America, Central America, Mexico and parts of the United States that is most commonly transmitted by blood transfusion. T.cruzi is responsible for the development of Chagas' disease, which can develop into fatal infectious heart disease. Current diagnostic procedures to determine blood exposure to T. cruzi infection are based on the detection of patient antibodies that react with crude extracts of this parasite. These tests often produce false results due to their inability to distinguish antibodies against T. cruzi from antibodies against other infectious agents. The Company has discovered and evaluated in vitro a number of peptides encoded by genes of the T. cruzi parasite for their ability to serve as highly specific and sensitive reagents for detection of T. cruzi. Corixa has licensed its T. cruzi antigen technology for the development of both blood screen and point-of-care diagnostic tests to several diagnostic companies, including DiaMed S.A. ("DiaMed") and Trinity Biotech U.K. Limited ("Trinity Biotech" formerly Centocor, U.K.).